M&A Deal Summary |
|
|---|---|
| Date | 2025-10-16 |
| Target | Brifer |
| Sector | Transportation |
| Buyer(s) |
Siparex
Bpifrance Investissement |
| Deal Type | Buyout (LBO, MBO, MBI) |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1977 |
| PE ASSETS | 4.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
Siparex is a French private equity firm that looks to invest mezzanine or equity capital in companies at all stages of development. The Firm separates its investment activity into mid-market, mezzanine, and small-cap. Within mid-market, Siparex looks to invest €2.5 to €40 million in companies with at least €15 million in sales. Prospective transaction situations include buyouts, shareholder liquidity events, and growth capital financings. The Firm will consider all business sectors. Within its mezzanine group, Siparex looks to invest €2 to €10 million to support growth, acquisitions, refinancings, and restructurings. The small-cap group seeks investments starting at €300K in early-stage companies as well as those undergoing expansion or being sold. Siparex was formed in 1977 and is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 102 of 102 |
| Sector: Transportation M&A | 7 of 7 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 33 of 33 |
| Country: France M&A | 95 of 95 |
| Year: 2025 M&A | 7 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-07 |
Serapid
Martin Eglise, France Serapid specializes in the vertical and horizontal movement of loads for industry, quick die change and stage engineering. Serapid was founded in 1972 and is based in Martin Eglise, France. |
Buy | - |
| DEAL STATS | # |
|---|---|
| Overall | 115 of 115 |
| Sector: Transportation M&A | 9 of 9 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 33 of 33 |
| Country: France M&A | 114 of 114 |
| Year: 2025 M&A | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-04-23 |
NOOUS
Labege, France NOOUS provides human-resources consulting, externalisation and digital-tools services for organizations internationally. The Company supports clients across sectors in areas such as HR strategy, training and compliance, alternance and internships, and software solutions for HR management. NOOUS was founded in 1999 and is based in Labege, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-22 |
Imcheck Therapeutics
Marseilles, France ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France. |
Sell | - |
